Lixte Biotechnology Holdings Inc
LIXT
Get informed when a big investor buys or sells
+ FollowMarket Cap$89.11M
Close$
$0.09
98.7% downside
Current Fair Value
98.7% downsideOvervalued by 98.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $89.11 Million |
|---|---|
| Enterprise Value | $77.55 Million |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $-1.26 |
| Beta | 1.25 |
| Outstanding Shares | 13,475,293 |
Return
| Return on Equity | -25432.42% |
|---|---|
| Return on Assets | -22819.87% |
| Return on Invested Capital | -20320.91% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 7.21 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.02 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Lixte Biotechnology Holdings Inc
4 employeesLixte Biotechnology Holdings, Inc. is a biotech company that identifies enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Lixte's product pipeline is primarily focused on inh...